Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The Download: AI’s impact on jobs, and data centres in space

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: AI’s impact on jobs, and data centres in space Date: 2026-04-07 12:10 Source: https://www.technologyreview.com/2026/04/07/1135208/the-download-ai-impact-jobs-data-centres-space/ <p><em>This is today’s edition of </em><a href="https://forms.technologyreview.com/ne…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Any plan to address AI's impact on jobs will depend on collecting one vital piece of data: price elasticity

    60% confidence

  • Critics warn that Apple's industrial eucalyptus tree farms will do more harm than good for the environment

    60% confidence

  • Top research talent is already fleeing the United States due to funding cuts

    60% confidence

  • It was actually quite nice when Artemis II was out of communication with the rest of humanity

    60% confidence

  • Elon Musk coordinated attacks with Mark Zuckerberg against OpenAI

    60% confidence

  • Many OpenAI insiders don't trust Sam Altman

    60% confidence

  • Some OpenAI insiders have called Sam Altman a sociopath

    60% confidence

  • Elon Musk is trying to take control of the future of AGI

    60% confidence

  • If Trump gets his way, the US could face a costly brain drain

    60% confidence

  • Chinese tech firms are selling intelligence exposing US forces by combining AI with open-source data

    60% confidence

  • We need a Manhattan Project for collecting price elasticity data on AI's job impact

    60% confidence

  • OpenAI's CFO fears it won't be IPO-ready this year

    60% confidence

Data points we hold from this source

SpaceX · orbital data centers planned1000000 units
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com